Compare ZUMZ & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZUMZ | CCCC |
|---|---|---|
| Founded | 1978 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.7M | 404.7M |
| IPO Year | 2005 | 2020 |
| Metric | ZUMZ | CCCC |
|---|---|---|
| Price | $18.39 | $3.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $18.00 | $12.20 |
| AVG Volume (30 Days) | 202.0K | ★ 2.3M |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 966.67 | 16.45 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $929,057,000.00 | $35,947,000.00 |
| Revenue This Year | $4.30 | N/A |
| Revenue Next Year | $3.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.48 | 1.02 |
| 52 Week Low | $11.97 | $1.36 |
| 52 Week High | $31.70 | $4.60 |
| Indicator | ZUMZ | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 33.17 | 56.80 |
| Support Level | $15.00 | $2.17 |
| Resistance Level | $22.91 | $4.60 |
| Average True Range (ATR) | 1.24 | 0.40 |
| MACD | -0.55 | -0.04 |
| Stochastic Oscillator | 32.92 | 42.33 |
Zumiez Inc is a United States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art, action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.